ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical-stage oncology company, will participate in two June 2026 investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical-stage oncology company, will participate in two June 2026 investor conferences. Management joins fireside chats at the Jefferies Global Healthcare Conference on June 3 at 11:40 a.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 at 8:00 a.m. ET.
Both fireside chats, along with replays available for 90 days, can be accessed via webcasts in the investor section of ORIC’s website. Management will also hold one-on-one investor meetings at each event.
Details
News Market Reaction – ORIC
On May 28, the first trading day after this news, ORIC closed 1.52% below the previous close.
Data tracked by StockTitan Argus for the May 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in June:
- Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 3, 2026, at 11:40 a.m. ET. Management will also be participating in one-on-one meetings.
- Goldman Sachs 47th Annual Global Healthcare Conference – Participating in a fireside chat on Tuesday, June 9, 2026, at 8:00 a.m. ET. Management will also be participating in one-on-one meetings.
Webcasts of the fireside chat discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.